Sulbactam–durlobactam for infections caused by Acinetobacter baumannii–calcoaceticus complex – Authors' reply

Results from the ATTACK trial show the safety and efficacy of sulbactam–durlobactam for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of ABC. Individual treatment approaches will need to be established on a case-by-case basis on the basis of the clinical condition of each patient, microbiological findings, and local bacterial-susceptibility profiles. KSK was a member of the Data Safety Monitoring Committee for the ATTACK trial; has received consulting fees from Entasis Therapeutics, Merck, Shionogi, Qpex Biopharma, GlaxoSmithKline, MicuRx Pharmaceuticals, AbbVie, Johnson & Johnson, Venatorx Pharmaceuticals, and Allecra Therapeutics; and owns stock options in Merck.